Phase 2 N=3 A Study of ELX-02 in Patients With Alport Syndrome
Alport Syndrome
Primary: Number of Participants With Adverse Events Associated With Administration of 0.75 mg/kg of ELX-02 Once Daily — 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=44 A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome
Alport Syndrome · Kidney Disease
Primary: Number of Subjects Developing Microalbuminuria During Study Period — 35 Participants
Phase 2 N=20 A Study to Evaluate Setanaxib in Patients With Alport Syndrome
Alport Syndrome
Primary: Percentage of Patients With Serious Adverse Events (SAEs) — 1; 0 Participants
Phase 3 N=187 A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL
Alport Syndrome
Primary: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) After 12 Weeks of Treatment (Phase 2) — 13.37 mL/min/1.73 m^2 — p=<0.0001
Phase 2 N=21 Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
IgA Nephropathy · Lupus Nephritis · Membranous Nephropathy
Primary: Part A: Change From Baseline in Proteinuria at Week 48 — -0.1364; 0.3560; 0.3430; -2.0347 ratio
Phase 2 N=15 Permeability Factor in Focal Segmental Glomerulosclerosis
Focal Segmental Glomerulosclerosis
Primary: Reduction in Proteinuria in Recurrent FSGS Following Renal Transplant With Plasma Exchange and Cyclophosphamide. — 0; 0; 0.5; 0.25 proportion of participants with…
Phase 4 N=63 Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria
Idiopathic Focal Segmental Glomerulosclerosis
Primary: Number of Participants With Adverse Events — 0; 11; 60 Participants
Phase 4 N=153 Angiotensin II Blockade for Chronic Allograft Nephropathy
Kidney Disease · Proteinuria
Primary: Doubling of Interstitium or Any ESRD — 6; 12 Participants
Phase 4 N=16 Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH
Kidney Diseases
Primary: 24 Hour Proteinuria — 3.6; 3.8; 2.2; 3.0 g/day
Phase 2 N=23 Gene Therapy for Achromatopsia (CNGB3)
Achromatopsia
Primary: Number of Participants Meeting the Primary Outcome Defined as Any of the Below Events Occurring During the 6 Weeks Following Administration, at Least Possibly Related to…
Phase 2 N=12 Podocyte Retinoids
Collapsing Glomerulopathy · Glomerulosclerosis, Focal Segmental
Primary: Change in Proteinuria at Week 24 From Baseline — 8.42; 7.67 g/g
Phase 2 N=11 Gene Therapy for Achromatopsia (CNGA3)
Achromatopsia
Primary: Number of Participants Meeting the Primary Outcome Defined as Any of the Below Events Occurring During the 6 Weeks Following Administration, at Least Possibly Related to…
N/A N=7 Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome
Focal Segmental Glomerulosclerosis · Steroid Resistant Nephrotic Syndrome
Primary: Focal Segmental Glomerulosclerosis Permeability Factor (FSPF) — 0.69; 0.35 Palb — p=0.009
Phase 2 N=16 Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis
Glomerulosclerosis, Focal Segmental
Primary: Percent Change From Baseline in UPCR — -47.7; -47.5; -47.6 percent change
Phase 3 N=371 Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis
Primary: Slope of Estimated Glomerular Filtration Rate (eGFR) — -5.4; -5.7 milliliters/minute/1.73square meter/year — p=0.7491
Phase 3 N=530 A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
Diabetic Nephropathies · Coronary Artery Disease
Primary: iGFR at the End of the Wash-out Period — 61.2; 61.2 ml/min/1.73 m^2 — p=0.999
N/A N=2 Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease
Multiple Myeloma · Amyloidosis
Primary: Number of Participants Without Renal Allograft Rejection at 6 Months Post-transplant — 1 Participants
Phase 4 N=28 Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes · Hypertension
Primary: Change in Urine Microalbumin Creatinine Ratio — 15 mg/g
Phase 2 N=23 Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial
Focal Segmental Glomerulosclerosis
Primary: Number of Participants With a Reduction in Proteinuria at 6 Months by > 50% of the Value at Screening AND Stable GFR Defined as Greater Than 75 ml/Min/1.73m2 in Those…
Phase 3 N=558 HALT Progression of Polycystic Kidney Disease Study A
Kidney, Polycystic
Primary: Study A: Percent Annual Change in Total Kidney Volume — 6.0; 6.2; 5.6; 6.6 percentage of Total Kidney Volume — p=0.52
Phase 3 N=486 HALT Progression of Polycystic Kidney Disease Study B
Kidney, Polycystic
Primary: Number of Participants With 50% Reduction of Baseline eGFR, End Stage Renal Disease (ESRD, Initiation of Dialysis or Preemptive Transplant), or Death. — 116; 115…
Phase 4 N=15 Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)
Treatment Resistant Nephrotic Syndrome
Primary: Significant Reduction in Proteinuria to Remission Levels During the Treatment Period (Includes Complete and Partial Remission, as Defined in the Outcome Measure…
Phase 4 N=5 Adrenocorticotropic Hormone in Membranous Nephropathy
Membranous Nephropathy
Primary: Change in Proteinuria — 4.56; 1.36 ratio
Phase 3 N=30 Comparison of Aliskiren vs Negative Controls on Aortic Stiffness in Patients With MFS
Marfan Syndrome
Primary: Central Aortic Distensibility by MRI — 3.7; 4.7; 5.7; 5.1 (mmHg ^ -1) x 10 ^ -3
Phase 2 N=169 Bosutinib For Autosomal Dominant Polycystic Kidney Disease
Polycystic Kidney, Autosomal Dominant
Primary: Change From Baseline (CFB) in Total Kidney Volume (TKV) at Month 25 — 1686.38; 1418.96; 1487.48; 1670.33 centimeter cube (cm^3) — p=<0.0001
Phase 2 N=21 Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)
Fibrosis · Focal Glomerulosclerosis · Kidney Failure
Primary: Decrease in GFR During Treatment Period — -0.45 ml/min/1.73 m2 — p=<0.01
N/A N=2,050 Genetic Testing to Understand and Address Renal Disease Disparities
Hypertension · Chronic Kidney Disease · Genomics
Primary: Number of Participants With Urine Protein Excretion — 33; 278; 39; 50 Participants
Phase 4 N=128 ARIA (Atacand Renoprotection In NephropAthy Pt.)
Non-diabetic Nephropathy With Hypertension
Primary: The Change in Urinary Protein/Creatinine Ratio From Baseline to 28 Weeks — 794.0; 639.9; 819.0 mg/g
Phase 2 N=36 Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)
Nephrotic Syndrome · Focal Segmental Glomerulosclerosis · Minimal Change Disease
Primary: Percentage of Participants in Renal Response at Day 113 — 0.0; 7.7; 12.5; 33.3 Percent of Participants
N/A N=442 Cerebrotendinous Xanthomatosis (CTX) Prevalence Study
Cerebrotendinous Xanthomatosis (CTX)
Primary: Number of Participants Who Had Positive Genetic Test Results — 4 Participants